Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC by Zhou, Qing, XX, Soo, Ross A., XX, Chang, Gee-Chen, XX, Chiu, Chao-Hua, XX, Hayashi, Hidetoshi, XX, Kim, Sang-We, XX, Teraoka, Shunsuke, XX, Goto, Yasushi, XX, Zhou, Jianying, XX, Ho-Fun Lee, Victor, XX, Kim, Dong-Wan, XX, Han, Baohui, XX, Chung Man Ho, James, XX, Lin, Chia-Chi, XX, Lu, Shun, XX, Polli, Anna, XX, Calella, Anna Maria, XX, Martini, Jean-François, XX, Wong, Chew Hooi, XX, Mok, Tony, XX, Kim, Hye Ryun, XX, Wu, Yi-Long, MD

Get full text